1. respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. 2. known medical resuscitation within 14 days of randomization 3. pregnant or breast feeding 4. suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) 5. alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). 6. uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll 7. treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

1. respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. 2. known medical resuscitation within 14 days of randomization 3. pregnant or breast feeding 4. suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) 5. alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). 6. uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll 7. treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. known medical resuscitation within 14 days of randomization pregnant or breast feeding suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. known medical resuscitation within 14 days of randomization pregnant or breast feeding suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

1. respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. 2. known medical resuscitation within 14 days of randomization 3. pregnant or breast feeding 4. suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) 5. alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). 6. uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll 7. treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

1. respiratory failure at the time of screening due to covid-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills. 2. known medical resuscitation within 14 days of randomization 3. pregnant or breast feeding 4. suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with sars-cov-2) 5. alanine aminotransferase (alt), and/or aspartate aminotransferase (ast) and/or bilirubin ≥ 3x upper limit of normal (uln) and/or severe hepatic impairment detected during the screening period (per local lab) exception: ast and/or alt ≤5 × uln if considered due to underlying covid-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × uln). 6. uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (nyha grade 3 or 4). exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll 7. treatment with a strong cytochrome p450 (cyp)3a inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).